What is a stock summary page? Click here for an overview.
Business Description
Checkpoint Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1628281073
Description
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -2.43 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -117.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -70.3 | |||||
| 3-Year EBITDA Growth Rate | 12.5 | |||||
| 3-Year EPS without NRI Growth Rate | 8.1 | |||||
| 3-Year FCF Growth Rate | 5 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 2006.62 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 82.73 | |||||
| 9-Day RSI | 74.27 | |||||
| 14-Day RSI | 67.72 | |||||
| 3-1 Month Momentum % | -16.53 | |||||
| 6-1 Month Momentum % | 29.88 | |||||
| 12-1 Month Momentum % | 64.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.29 | |||||
| Quick Ratio | 0.29 | |||||
| Cash Ratio | 0.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -58.7 | |||||
| Shareholder Yield % | -11.59 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -79817.02 | |||||
| Net Margin % | -98868.09 | |||||
| FCF Margin % | -65440.43 | |||||
| ROA % | -763.77 | |||||
| ROIC % | -2671.94 | |||||
| 3-Year ROIIC % | -3636.56 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4040.05 | |||||
| EV-to-EBIT | -5.87 | |||||
| EV-to-Forward-EBIT | -3.17 | |||||
| EV-to-EBITDA | -5.87 | |||||
| EV-to-Forward-EBITDA | -3.17 | |||||
| EV-to-Revenue | 4685.32 | |||||
| EV-to-Forward-Revenue | 3.02 | |||||
| EV-to-FCF | -7.14 | |||||
| Price-to-GF-Value | 11.91 | |||||
| Earnings Yield (Greenblatt) % | -17.04 | |||||
| FCF Yield % | -13.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CKPT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Checkpoint Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.047 | ||
| EPS (TTM) ($) | -1.84 | ||
| Beta | 1.58 | ||
| 3-Year Sharpe Ratio | -0.36 | ||
| 3-Year Sortino Ratio | -0.51 | ||
| Volatility % | 86.51 | ||
| 14-Day RSI | 67.72 | ||
| 14-Day ATR ($) | 0.181567 | ||
| 20-Day SMA ($) | 3.33775 | ||
| 12-1 Month Momentum % | 64.74 | ||
| 52-Week Range ($) | 1.38 - 4.5 | ||
| Shares Outstanding (Mil) | 55.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Checkpoint Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Checkpoint Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Checkpoint Therapeutics Inc Frequently Asked Questions
What is Checkpoint Therapeutics Inc(CKPT)'s stock price today?
The current price of CKPT is $4.05. The 52 week high of CKPT is $4.50 and 52 week low is $1.38.
When is next earnings date of Checkpoint Therapeutics Inc(CKPT)?
The next earnings date of Checkpoint Therapeutics Inc(CKPT) is 2025-05-09 Est..
Does Checkpoint Therapeutics Inc(CKPT) pay dividends? If so, how much?
Checkpoint Therapeutics Inc(CKPT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers